December 11, 2007

Dear Board Members:

Annual Report to the Board

This report is presented to the Board of Directors at the 2007 annual meeting of CLL Topics, Inc.

It has been an eventful year with a number of important achievements in supporting clinical research in CLL and in our patient education and advocacy mission.

1. We proposed a clinical trial to test the efficacy of imiquimod as an adjuvant in pneumonia vaccination in CLL patients and negotiated an agreement with Dr. Kenneth Foon at the University of Pittsburgh Medical Center to conduct this trial based on our sponsorship and a supporting grant of $75,000. The trial protocol is now under regulatory review at UPMC and Professor Foon expects action in the next few months.

2. We disbursed our grant of $20,000 to the Fred Hutchinson Cancer Research Center at the University of Washington, Seattle, WA for a study to evaluate the combination of fenretinide and Rituxan as a therapeutic protocol for CLL. The principal investigator for this trial is Professor Ajay Gopal. Our support of this trial, which is substantially funded by the NCI, was instrumental in having CLL patients included in the study.

3. The "Jab & Dab" clinical trial concept we proposed to Professor Terry Hamblin at the Royal Bournemouth Hospital in the UK has received regulatory approval and is currently recruiting patients. The principal investigator and our collaborator for this trial is Dr. Helen McCarthy at the Royal Bournemouth Hospital. Our sponsorship grant of $20,000 was disbursed to the Bournemouth Leukemia Fund in October. This trial will test the efficacy of imiquimod as an immune modulator to increase the response rate of CLL patients to influenza vaccination.

4. Our collaboration with Mayo Clinic, Rochester and leadership in the data collection process for the Quality of Life web survey has resulted in the publication of the first of a series of planned articles in professional medical journals. Chaya Venkat is a co-author on these articles and CLL Topics, Inc. is identified as a collaborating institution.

5. Initial results from our EGCG clinical trial at Mayo Clinic, Rochester, MN, are encouraging. The dose escalation phase of this trial has produced very encouraging early results. The results will be presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta. We are extremely pleased at these early results, particularly in view of the low toxicity of the agent involved and the fact that
his is the first clinical trial we sponsored with patient donations. The phase II portion of this trial is currently recruiting patients at Mayo Clinic.

6. CLL Topics, Inc. applied for and received approval for inclusion as a sponsoring institution for clinical trials in the U. S. Government’s clinicaltrials.gov trial registry.

7. Since the date of our incorporation as a non-profit our fund-raising now stands at $306,753.34 from 555 donors, principally CLL patients and their families and friends.

8. Donations received this year through December 11, 2007 have totaled $119,252.00, of which $80,000 was from a single donor who wishes to remain anonymous. This donation is categorized as an “unusual grant” since it does not conform to our normal fundraising profile.

9. As of this date, the Corporation’s reserves amount to $168,947.16.

10. As of June 30, 2007 we stopped accepting new donations to CLL Topics since we had reached our fundraising goals for the year and did not need additional funds to meet our existing commitments and, in addition, given the planned stem cell transplant for one of our two full-time volunteers, we decided to reduce our administrative load to focus our activities on our publishing operations.

11. Topics Alerts has increased its subscriber enrollment to 2,109. Fifty five Alerts have been issued so far this year.

12. Since January 2007, we have published twenty four new articles on the website.

13. We have completed a major re-write of entire CLL Topics website, implementing standards-compliant code to accommodate evolving Internet standards. We have maintained exactly 100% uptime through the year.

14. Traffic to the CLL Topics online publication has averaged between 30,000 and 45,000 visits a month during 2007.

15. The website generates a constant stream of feedback, almost entirely positive, and many requests for information and assistance. The officers of the Corporation currently respond to over 1,000 email communications a month from patients and professionals in the field.

16. We have also received a number of calls from the financial press and PR firms interested in our discussion of drugs used in the treatment of CLL and the companies that manufacture or market them. We continue to be selective in our responses to these contacts.

17. We have completed four years of regulatory reporting to the State of Arizona and the IRS. We have received notification from the IRS that we are at the end of the advance ruling period for our non-profit status. We have been given 90 days to file a form 8734 to establish that we are a publicly supported non-profit.

18. We continue to be registered with Guidestar, the national database of non-profit organizations, and HONCode, the Geneva based registry of health information providers.

19. Given the CLL treatment schedule for our editor and publisher and other constraints, we have decided not to send a team of reporters to the 2007 Annual Meeting of the American Society of Hematology in Atlanta, GA, this month.

20. We have recruited two additional volunteers to assist in our web publishing operations during the period covering the stem cell transplant for P. C. Venkat. Radha

Dedicated to the Fight Against Chronic Lymphocytic Leukemia
Venkat and Chino Rao have generously agreed to volunteer their services to assist in this effort.

21. We are saddened to report the deaths of two of our former Board members during the year. Mr. William W. Duffy, II and Dr. Judith E. Fisher served on our Board since its formation in 2003. We are grateful for their generous contribution of time, energy and talents to our cause. We have conveyed our heartfelt sympathy to their families.

We would like to thank the members of the outgoing Board of Directors that was elected to office for the interim term between July 1, 2007 and December 31, 2007. Their guidance, oversight and assistance have been extremely valuable. We are very pleased that all members of the outgoing Board have agreed to our request to stay on as members of the new Board for 2008 and contribute their efforts, time and talents to our mission for another year.

It is with pleasure we announce the following slate of directors for re-election in our annual meeting of December 11, 2007:

Loyd Keith Friedlander,
Wendy Ramsey,
Chaya Venkat,
P. C. Venkat.

Very truly yours,

_____________________
Chaya Venkat
President
& Treasurer
CLL Topics, Inc.

_____________________
P. C. Venkat
Vice President
& Secretary
CLL Topics, Inc.